Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 1/20 | 0.51 |
| ▸ | NAAA | Q02083 | 1/20 | 0.51 |
| ▸ | FDPS | P14324 | 4/20 | 0.39 |
| ▸ | CCR2 | P41597 | 1/20 | 0.37 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.36 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.36 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.36 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.36 |
| ▸ | GPR84 | Q9NQS5 | 4/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.35 |
| ▸ | DHPS | P49366 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23921699 | 1.00 | FAAH (0.51) | FAAHNAAAFDPSCCR2GNAI3 | |
| SCHEMBL21283589 | 0.90 | FAAH (0.45) | FAAHNAAAFDPSCCR2GNAI3 | |
| SCHEMBL20878441 | 0.90 | FAAH (0.45) | FAAHNAAAFDPSCCR2GNAI3 | |
| SCHEMBL22017687 | 0.85 | FAAH (0.41) | FAAHNAAAFDPSCCR2GNAI3 | |
| SCHEMBL23608119 | 0.85 | FAAH (0.41) | FAAHNAAAFDPSCCR2GNAI3 | |
| SCHEMBL25687608 | 0.85 | FAAH (0.46) | FAAHNAAACCR2GNAI3GNAO1 | |
| SCHEMBL25131961 | 0.79 | GNAI3 (0.37) | FAAHNAAAFDPSCCR2GNAI3 | |
| SCHEMBL25653283 | 0.79 | GNAI3 (0.37) | FAAHNAAAFDPSCCR2GNAI3 | |
| SCHEMBL5820466 | 0.78 | FAAH (0.40) | FAAHNAAAMEN1KMT2A | |
| SCHEMBL24772662 | 0.77 | FAAH (0.41) | FAAHNAAACCR2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230103415-A1 | SMARCA INHIBITORS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230103415-A1 | SMARCA INHIBITORS AND USES THEREOF | SMARCC1, SMARCE1, SMARCA1 | FAAH 4493/4885NAAA 2742/4885FDPS 3743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.